Ziccum AB (publ) share issue oversubscribed before listing on Spotlight

STOCKHOLM, SWEDEN 9 October. On October 3, 2018, the subscription period for Ziccum's new issue of units was completed, prior to its planned listing on Spotlight. The new issue of 15.8 MSEK was subscribed to approximately 52.7 MSEK including subscription commitments, a subscription ratio of approximately 334%. Ziccum will therefore receive a total of 15.8 MSEK before issue costs of approx. 1 MSEK, while increasing the number of shareholders to approximately 1000. Settlement notes for units subscribed without preference under the new terms and conditions was issued on October 8, 2018.

CEO Göran Conradson’s statement:

"It’s gratifying that the new issue has been fully subscribed and we can now begin speeding up the development of our projects. We believe that Ziccum’s unique technology has significant medical and commercial potential, and I look forward to keeping investors informed as our projects move forward and approach market. I’d like to offer a warm welcome to all Ziccum AB’s new owners!"

Chairman of the Board of Inhalation Sciences AB, Fredrik Sjövall’s, statement:

“We are, of course, enormously pleased that Ziccum has been so well received by both inhalation Sciences’ owners and new investors. The fact that we’ve now reached the goal of financing Ziccum's continued development is an important milestone for ISAB—and it’s good for our shareholders in both the short and long term. We would like to thank all ISAB owners who showed their confidence in us by taking part in this share issue.”

Ziccum was founded as a spin-out from Inhalation Sciences, which was successfully noted on Spotlight (formerly Aktietorget) in September 2017. Ziccum's vision is to enable the delivery of safe and effective drugs to all environments worldwide, minimizing costly and impractical fridge and freezer transport and storage.

Advisors

Fredersen Advokatbyrå AB has acted as legal adviser in connection with the issue. Aqurat Fondkommission AB has acted as the issuer.

For more information about Ziccum, please contact: Göran Conradson: CEO Ziccum AB E-mail: conradson@ziccum.com Mob: +46 709 61 55 99 For more information on Inhalation Sciences, please contact: Lena Heffler, CEO E-post: lena.heffler@inhalation.se Call: +46 (0)70 205 9620